These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 26222534)

  • 1. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
    Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
    Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.
    Gaba RC; Zivin SP; Dikopf MS; Parvinian A; Casadaban LC; Lu Y; Bui JT
    Radiology; 2014 May; 271(2):602-12. PubMed ID: 24533871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic
    Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H
    AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460
    [No Abstract]   [Full Text] [Related]  

  • 5. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
    Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
    Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Hickey R; Kulik L; Desai K; Yang Y; Gates VL; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1213-1222. PubMed ID: 28280976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Mar; 56(3):333-8. PubMed ID: 25655623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.
    Ulrich G; Dudeck O; Furth C; Ruf J; Grosser OS; Adolf D; Stiebler M; Ricke J; Amthauer H
    J Nucl Med; 2013 Apr; 54(4):516-22. PubMed ID: 23447653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with
    Narsinh KH; Van Buskirk M; Kennedy AS; Suhail M; Alsaikhan N; Hoh CK; Thurston K; Minocha J; Ball DS; Cohen SJ; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kanani S; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA; Rose SC
    Radiology; 2017 Jan; 282(1):281-288. PubMed ID: 27440733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation.
    Gabr A; Ranganathan S; Mouli SK; Riaz A; Gates VL; Kulik L; Ganger D; Maddur H; Moore C; Hohlastos E; Katariya N; Caicedo JC; Kalyan A; Lewandowski RJ; Salem R
    J Hepatol; 2020 Jun; 72(6):1151-1158. PubMed ID: 32145255
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Nezami N; Kokabi N; Camacho JC; Schuster DM; Xing M; Kim HS
    Nucl Med Biol; 2018 Apr; 59():22-28. PubMed ID: 29448165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?
    Elsayed M; Cheng B; Xing M; Sethi I; Brandon D; Schuster DM; Bercu Z; Galt J; Barron B; Kokabi N
    Cardiovasc Intervent Radiol; 2021 Feb; 44(2):254-260. PubMed ID: 33000319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors modulating
    Lopez BP; Mahvash A; Long JP; Lam MGEH; Kappadath SC
    J Appl Clin Med Phys; 2022 Dec; 23(12):e13734. PubMed ID: 35906892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.
    Haug AR; Heinemann V; Bruns CJ; Hoffmann R; Jakobs T; Bartenstein P; Hacker M
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1037-45. PubMed ID: 21308371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tc-99m-MAA lung shunt fraction before Y-90 radioembolization is low among patients with non-hepatocellular carcinoma malignancies.
    Elsayed M; Martin JG; Dabrowiecki A; Goldman DT; Faraj R; McMahon JT; Kokabi N; Duszak R; Newsome J; Bercu ZL
    Nucl Med Commun; 2019 Nov; 40(11):1154-1157. PubMed ID: 31568192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging Predictors of Elevated Lung Shunt Fraction in Patients Being Considered for Yttrium-90 Radioembolization.
    Olorunsola OG; Kohi MP; Behr SC; Kolli PK; Taylor AG; Tong RT; LaBerge JM; Kerlan RK; Fidelman N
    J Vasc Interv Radiol; 2015 Oct; 26(10):1472-8. PubMed ID: 26296737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeat Evaluation of Lung Shunt Fraction is Unnecessary: A Retrospective Observational Study of Successive Lung Shunt Fractions from Variable Arterial Distributions in Patients Undergoing Radioembolization of Primary and Secondary Liver Tumors.
    Bulman JC; Zurkiya O; Wu V; Wehrenberg-Klee E; Palmer E; Chow D; Brook A; Ganguli S
    J Vasc Interv Radiol; 2021 Mar; 32(3):412-418. PubMed ID: 33341340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.